Overview: Initial and long-term management of gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 17, Issue 1, 2003, Pages 53-57

  Dent, J ^a   Talley, N J ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; GASTROESOPHAGEAL REFLUX; HEALING; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REFLUX ESOPHAGITIS; RISK MANAGEMENT; SIDE EFFECT; SYMPTOM; TREATMENT FAILURE;

DECISION MAKING; GASTROESOPHAGEAL REFLUX; HUMANS; LONG-TERM CARE; PROTON PUMPS; RISK FACTORS; RISK MANAGEMENT; TREATMENT FAILURE;

EID: 0037325269     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01356.x     Document Type: Conference Paper

References (15)

1. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
2. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-8.
3. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999; 44(Suppl. 2): S1-16.
4. Howden C, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 1704-10.
5. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999; 94: 92-7.
6. Klinkenberg-Knol EC, Nelis F, Dent J. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
7. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
8. Malfertheiner P, Mégraud F, O'Moràin C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 167-80.
9. Venables TL, Newland RD, Patel AC, et al. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997; 32: 627-32.
10. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318: 502-7.
11. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomised trial. Aliment Pharmacol Ther 1999; 13: 907-14.
12. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54.
13. O'Connor JB, Provenzale D, Brazer S. Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am J Gastroenterol 2000; 95: 3356-64.
14. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6.
15. Katz PO, Anderson C, Khoury R, Castell DO. Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.